CHICAGO: US cancer diagnostic test maker Grail, which was due to list its shares on the Nasdaq yesterday after being spun out of Illumina, is betting that commercial partnerships with health systems, employers and life insurance companies of its flagship cancer-detection test will power its near-term growth as an independent company.
The blood test, called Galleri, can detect multiple types of cancer early and targets 80% of cancers currently not screened for that result in cancer deaths, Grail chief executive officer Bob Ragusa said in a interview on Monday.
